Compare FTCI & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTCI | ACOG |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United States | Canada |
| Employees | N/A | 57 |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.4M | 110.4M |
| IPO Year | 2021 | N/A |
| Metric | FTCI | ACOG |
|---|---|---|
| Price | $5.04 | $7.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $10.80 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 90.5K | 30.0K |
| Earning Date | 05-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,687,000.00 | N/A |
| Revenue This Year | $65.44 | $139.22 |
| Revenue Next Year | $45.97 | $134.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 110.51 | N/A |
| 52 Week Low | $3.21 | $4.50 |
| 52 Week High | $12.75 | $10.88 |
| Indicator | FTCI | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 69.57 |
| Support Level | $4.20 | $6.46 |
| Resistance Level | $5.31 | $7.69 |
| Average True Range (ATR) | 0.48 | 0.36 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 45.98 | 99.50 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.